Experiences with CB-03-01? 11/7/2015
CB-03-01 is considered too costly and lacks a proper delivery method, making it less viable compared to RU58841, which has shown effectiveness with minimal side effects. Finasteride caused a drop in libido for one user.
View this post in the Community →
Similar Community Posts Join
6 / 6 resultscommunity Possible explaination for Finasteride Reflex Hyperandrogenicity
The user has been using finasteride and minoxidil for hair loss but experienced worsening temple recession. They suspect they might be more sensitive to testosterone and are considering trying RU58841 or CB 03 01 as additional treatments.
community Ultimate DHT/finasteride microdosing graph to replace the commonly one referenced on forums
Hair loss treatments, specifically, discussing the effectiveness and side effects of finasteride, minoxidil, and RU58841 in various microdoses. It also includes an updated graph which provides information on how different doses affect DHT levels, scalp skin and serum androgen levels, as well as hair count.
community What else is good. Besides the big 3.
Key treatments for hair preservation include minoxidil, finasteride/dutasteride, and microneedling, with additional options like specific shampoos, oils, biotin, zinc, tretinoin, clascoterone, and low-level laser therapy. Maintaining a healthy lifestyle, reducing stress, and addressing nutrient deficiencies can also support hair health.
community Clascoterone 5% Delivers Strong Phase 3 Hair-Growth Results
Clascoterone 5% solution shows strong potential for hair growth, offering a new treatment for alopecia with minimal side effects. It blocks androgen receptors locally and may be available by late 2026 or early 2027.
community Are there any reliable places to buy CB 03-01? I can't tolerate fin or RU
The conversation is about finding a reliable source for CB 03-01 as an alternative treatment for hair loss due to intolerance to finasteride and RU58841. The user is also considering minoxidil for temporary effectiveness.
community RU58841 vs. KX-826 vs. CB-03-01
RU58841 shows the strongest results despite weaker binding affinity, while KX-826 and CB-03-01 are more expensive and have minimal side effects. RU58841 is considered effective but has potential health risks if ingested; users report positive outcomes with RU58841 and finasteride.
Related Research
6 / 6 results
research Persistent escalation of alcohol consumption by mice exposed to brief episodes of social defeat stress: suppression by CRF-R1 antagonism
In this study, socially defeated mice showed increased alcohol consumption, and CRF-R1 antagonism selectively reduced drinking in these mice, suggesting a potential treatment target for stress-related alcohol use disorders.
research Compounding as a Current Therapeutic Option in Dermatology
This review discusses the current role and challenges of compounding in dermatology without presenting new research results; the authors suggest its resurgence in practice despite pharmaceutical alternatives.
research Nouvelles thérapeutiques dans la prise en charge de l’alopécie androgénétique
This thesis investigates the underlying mechanisms and treatment options for androgenetic alopecia, highlighting the molecular roles of androgens and genetic predispositions, and evaluates current and emerging therapies, such as PROTACs and Janus Kinase inhibitors, to enhance patient management.
research Topical ketoconazole: a systematic review of current dermatological applications and future developments
This review found topical ketoconazole to be highly effective against Malassezia-related skin conditions, though other treatments may outperform it for Tinea and Candida infections.
research Development of fluridil, a topical suppressor of the androgen receptor in androgenetic alopecia
In this study, using a novel topical androgen receptor suppressor, fluridil, significantly increased the percentage of growing hairs in males with androgenetic alopecia without systemic absorption or adverse side effects.
research Drug discovery for alopecia: gone today, hair tomorrow
This review discusses current knowledge on the biological mechanisms of different types of alopecia but reports no new clinical findings; the authors highlight future research directions, especially regarding epidermal stem cells and immune pathways.